Dalfampridine ER ( DrugBank: Dalfampridine )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05730738 (ClinicalTrials.gov)	June 1, 2021	5/12/2021	Dalfampridine in Egyptian Patients With Multiple Sclerosis	Effect of Dalfampridine on Gait Impairment, Cognition and Fatigue in Egyptian Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Dalfampridine ER, 10 Mg Oral Tablet, Extended Release;Drug: Placebo	Ain Shams University	NULL	Recruiting	18 Years	N/A	All	100	N/A	Egypt
2	NCT01356940 (ClinicalTrials.gov)	November 2010	18/5/2011	A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis	A Randomized Controlled Double-blind Cross-over Trial of Dalfampridine ER for Effect on Ambulatory Activity in People With Multiple Sclerosis	Multiple Sclerosis	Drug: dalfampridine ER;Drug: placebo	Brown, Theodore R., M.D., MPH	Acorda Therapeutics	Completed	18 Years	75 Years	All	43	Phase 4	United States